These findings emphasize that genetic changes may significantly confound the effect of promoter methylation, as previously acknowledged by other researchers [37], and that MGMT downregulation is the result of a combination of altered genetic and epigenetic mechanisms in high-grade gliomas. Here, MGMT is linked to central nervous system cancer.